Challenging Road Ahead for Cancer Drugs, Nuvalent Seeks to Break the Mold - Nuvalent (NASDAQ:NUVL)
Stifel initiated coverage on Nuvalent Inc (NASDAQ: NUVL), recognizing that adopting a bullish stance in anticipation of Phase 1 cancer drug data, mainly when derived from heavily pretreated patients, has proven unprofitable for approximately two years.
Source: benzinga.com